**Aliqopa™ (copanlisib)**

**Last Review Date:** September 30, 2019  
**Number:** MG.MM.PH.46

---

**Medical Guideline Disclaimer**

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

---

**Definitions**

Aliqopa (copanlisib): is a kinase inhibitor of phosphatidylinositol-3-kinase (PI3K) and works primarily through isoforms PI3K-alpha and PI3K-beta which are expressed in malignant B cells. The result may be tumor cell death via apoptosis and inhibition of proliferation of primary malignant B cell lines. Several important cell-signaling pathways are also inhibited by copanlisib, such as CXCR12 mediated chemotaxis of malignant B cells, B-cell receptor (BCR) signaling and NF-kappa-B signaling in lymphoma cell lines.

**Dosing**

Max Units (per dose and over time):

- 60 mg Days 1, 8, & 15 of a 28-day cycle

**Guideline**

Aliqopa (copanlisib) may be considered medically necessary when all of the following criteria are met:

- Patient is 18 years of age or older; **AND**
- Patient has a diagnosis of relapsed follicular lymphoma (FL); **AND**
- Aliqopa (copanlisib) is being used as a single-agent; **AND**
- Patient has failed at least two prior therapies.
Coverage for Aliqopa (copanlisib) may be renewed when the following criteria are met:

- Disease response; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: ≥ Grade 3 infections, uncontrolled hyperglycemia, uncontrolled hypertension, non-infectious pneumonitis, ANC < 0.5 x 103 cells/mm3, severe cutaneous reactions, etc.

**Limitations/Exclusions**

- Approval will be granted for 6 months, and may be renewed

**Revisions**

12/3/2018  Added J9057 and removed J9999, C9399 from Applicable Procedure Codes.

**Applicable Procedure Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9057</td>
<td>Injection, copanlisib, 1mg</td>
</tr>
</tbody>
</table>

**Applicable Diagnosis Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C82.00</td>
<td>Follicular lymphoma grade I, unspecified site</td>
</tr>
<tr>
<td>C82.01</td>
<td>Follicular lymphoma grade I, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C82.02</td>
<td>Follicular lymphoma grade I, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C82.03</td>
<td>Follicular lymphoma grade I, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C82.04</td>
<td>Follicular lymphoma grade I, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C82.05</td>
<td>Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C82.06</td>
<td>Follicular lymphoma grade I, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C82.07</td>
<td>Follicular lymphoma grade I, spleen</td>
</tr>
<tr>
<td>C82.08</td>
<td>Follicular lymphoma grade I, lymph nodes of multiple site</td>
</tr>
<tr>
<td>C82.09</td>
<td>Follicular lymphoma grade I, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C82.10</td>
<td>Follicular lymphoma grade II, unspecified site</td>
</tr>
<tr>
<td>C82.11</td>
<td>Follicular lymphoma grade II, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C82.12</td>
<td>Follicular lymphoma grade II, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C82.13</td>
<td>Follicular lymphoma grade II, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C82.14</td>
<td>Follicular lymphoma grade II, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C82.15</td>
<td>Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C82.16</td>
<td>Follicular lymphoma grade II, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C82.17</td>
<td>Follicular lymphoma grade II, spleen</td>
</tr>
<tr>
<td>C82.18</td>
<td>Follicular lymphoma grade II, lymph nodes of multiple site</td>
</tr>
<tr>
<td>C82.19</td>
<td>Follicular lymphoma grade II, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C82.20</td>
<td>Follicular lymphoma grade III, unspecified site</td>
</tr>
<tr>
<td>C82.21</td>
<td>Follicular lymphoma grade III, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C82.22</td>
<td>Follicular lymphoma grade III, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C82.23</td>
<td>Follicular lymphoma grade III, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C82.24</td>
<td>Follicular lymphoma grade III, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C82.25</td>
<td>Follicular lymphoma grade III, lymph nodes of inguinal region and lower limb</td>
</tr>
</tbody>
</table>
C82.26 Follicular lymphoma grade III, intrapelvic lymph nodes  
C82.27 Follicular lymphoma grade III, spleen  
C82.28 Follicular lymphoma grade III, lymph nodes of multiple site  
C82.29 Follicular lymphoma grade III, extranodal and solid organ sites  
C82.30 Follicular lymphoma grade IIla, unspecified site  
C82.31 Follicular lymphoma grade IIla, lymph nodes of head, face, and neck  
C82.32 Follicular lymphoma grade IIla, intrathoracic lymph nodes  
C82.33 Follicular lymphoma grade IIla, intra-abdominal lymph nodes  
C82.34 Follicular lymphoma grade IIla, lymph nodes of axilla and upper limb  
C82.35 Follicular lymphoma grade IIla, lymph nodes of inguinal region and lower limb  
C82.36 Follicular lymphoma grade IIla, intrapelvic lymph nodes  
C82.37 Follicular lymphoma grade IIla, spleen  
C82.38 Follicular lymphoma grade IIla, lymph nodes of multiple site  
C82.39 Follicular lymphoma grade IIla, extranodal and solid organ sites  
C82.40 Follicular lymphoma grade IIlb, unspecified site  
C82.41 Follicular lymphoma grade IIlb, lymph nodes of head, face, and neck  
C82.42 Follicular lymphoma grade IIlb, intrathoracic lymph nodes  
C82.43 Follicular lymphoma grade IIlb, intra-abdominal lymph nodes  
C82.44 Follicular lymphoma grade IIlb, lymph nodes of axilla and upper limb  
C82.45 Follicular lymphoma grade IIlb, lymph nodes of inguinal region and lower limb  
C82.46 Follicular lymphoma grade IIlb, intrapelvic lymph nodes  
C82.47 Follicular lymphoma grade IIlb, spleen  
C82.48 Follicular lymphoma grade IIlb, lymph nodes of multiple site  
C82.49 Follicular lymphoma grade IIlb, extranodal and solid organ sites  
C82.50 Other types of follicular lymphoma, unspecified site  
C82.51 Other types of follicular lymphoma, lymph nodes of head, face, and neck  
C82.52 Other types of follicular lymphoma, intrathoracic lymph nodes  
C82.53 Other types of follicular lymphoma, intra-abdominal lymph nodes  
C82.54 Other types of follicular lymphoma, lymph nodes of axilla and upper limb  
C82.55 Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb  
C82.56 Other types of follicular lymphoma, intrapelvic lymph nodes  
C82.57 Other types of follicular lymphoma, spleen  
C82.58 Other types of follicular lymphoma, lymph nodes of multiple site  
C82.59 Other types of follicular lymphoma, extranodal and solid organ sites  
C82.60 Follicular lymphoma, unspecified, unspecified site  
C82.61 Follicular lymphoma, unspecified, lymph nodes of head, face, and neck  
C82.62 Follicular lymphoma, unspecified, intrathoracic lymph nodes  
C82.63 Follicular lymphoma, unspecified, intrathoracic lymph nodes  
C82.64 Follicular lymphoma, unspecified, intra-abdominal lymph nodes  
C82.65 Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb  
C82.66 Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb  
C82.67 Follicular lymphoma, unspecified, intrapelvic lymph nodes  
C82.68 Follicular lymphoma, unspecified, spleen  
C82.69 Follicular lymphoma, unspecified, lymph nodes of multiple site  
C82.70 Follicular lymphoma, unspecified, extranodal and solid organ sites

References